This technology is a therapeutic platform that enables the selective removal of diseased or cancerous cells with few side effects.
Current treatments for cancer and immunological disease often lead to damage of healthy subpopulations of cells that share cell-surface markers with the diseased cells. Conventional treatment methods use bispecific antibodies to bind two or more antigens. However, these therapies have low specificity for their target and result in side effects.
This platform is comprised of multi-specific antibody pairs that self-assemble at the cell surface for the selective elimination of diseased cells. Antibody pairings on the same cell are crosslinked. This then triggers various events, such as internalization or activation of death receptor signaling pathways, and toxin delivery by attaching a load to the first antibody. This highly specified method of targeted antibody crosslinking avoids the side effects of conventional bispecific antibody-based immunotherapy.
IR CU21275
Licensing Contact: Jerry Kokoshka
